Imugene

Imugene Limited (IMU) is an Australian immuno-oncology focused Biopharmaceutical Company developing HER2 + ve gastric and breast cancer vaccines. The Group's lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu.

Details

37 Bligh Street , Suite 1006, Level 10 SYDNEY NSW 2000

info@imugene.com

www.imugene.com

Lists and Charts

Share price

Imugene

Closing price for the last 90 trading days

View ASX Chart

Total Shareholder Return as at 01/12/25

Rank	Company	1 Yr	5 Yr
1637^th	Anatara Lifesciences	-78.95%	-41.62%
1638^th	Biotron	-79.76%	-46.52%
1639^th	Imugene	-80%	-45.61%
1640^th	Synertec Corporation	-80%	-19.73%
1641^st	Tesoro Gold Ltd	-80%	-55.56%

View Full List

1675 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Company Share Transactions

Company Activity

	NEW ROLE: John Byon,	22 Sep 2025
	NEW ROLE: Bradley Glover,	04 Oct 2024
	NEW ROLE: Paul Woodard,	04 Oct 2024
	NEW ROLE: Kim Drapkin, Non-Executive Director	31 Jul 2024
	NEWS: Tagged in Cancer-fighting mission shoots Imugene up ASX boards	13 Nov 2023
	NEW ROLE: Giovanni Selvaggi,	30 Oct 2023
	NEW ROLE: Jakob Dupoint,	30 Oct 2023
	NEWS: Tagged in Healthtech banks on rising numbers	07 Nov 2022
	NEW ROLE: Monil Shah,	23 Sep 2022

News Articles

View All

Related Information

Access to our data for Imugene is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Imugene is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today